40 results about "Eclampsia preeclampsia" patented technology

Gene expression patterns contemporaneous with early placental development in the first trimester of preeclamptic versus unaffected pregnancies have been obtained. Observation of differences in these gene expression patterns has allowed the identification of biomarkers that are useful in predicting and monitoring preeclampsia. These biomarkers are also useful in screening potential therapeutics for efficacy in the prevention or treatment of preeclampsia.

The invention belongs to the fields of genetic engineering and clinical medicine, and discloses a related serum microribonucleic acid marker for human severe preeclampsia and application of the marker. The marker is selected from more of hsa-miR-193a-5p, hsa-miR-424 and hsa-miR-10a. The marker has the specificity and sensitivity on a sufferer with severe preeclampsia, and can be used for preparing a diagnosis or monitoring kit for severe preeclampsia.

The invention discloses application of umbilical cord mesenchymal stem cell-derived exosome in preparing drug or preparation for treating preeclampsia, in particular relates to application of treating preeclampsia by extracting exosome through umbilical cord mesenchymal stem cells of humans. The exosome can effectively alleviate hypertension and proteinuria of preeclampsia and glomerulonephritis, reduce inflammatory response in placenta, and promote fetal development. This kind of exosome has the advantages of convenience in storage and transport and provides a new strategy for treating related diseases of refractory inflammations of preeclampsia.

The invention discloses a siRNA-loaded nano-liposome hybrid micelle. The siRNA-loaded nano-liposome hybrid micelle comprises siRNA, cationic liposome and a lipid outer layer, wherein the the siRNA is coated by the cationic liposome from inside to outside. The siRNA provided by the invention can selectively silence three sFLT1 mRNAs subtypes of sFLT1 mainly causingover-express of a placenta, without decreasing the full-length FLT1 mRNA. The positively charged cationic liposome and the negatively charged siRNA are combined to form a compound, so that the stability of the siRNA is improved. After the compound is wrapped by the lipid outer layer, the placenta can be targeted, so that siRNAs are accumulated at the placenta, the uptake of cells to a delivery system is improved, and the escape of endosome is promoted. The invention further discloses a preparation method of the micelle and application of the micelle in preparation of drugs for treating preeclampsia, providing a new thought for gene therapy of preeclampsia.

The invention discloses a construction method and application of a preeclampsia mouse animal model. According to the construction method, the m6A modification level in a mouse is reduced, and a mutant mouse with the reduced RNA m6A modification level, namely the preeclampsia mouse animal model, is obtained; specifically, a Mett13<+ / >hybrid mutant mouse is constructed through an ES targeting technology, and a result shows that the sensitivity of the mutant mouse to a PE inducer L-NAME is increased, the mutant mouse presents the characteristics of PE, and a new thought and a new means are provided for etiological diagnosis, prevention and treatment of preeclampsia.

The invention discloses an establishing method of a hypertensive disorder complicating pregnancy mouse model. The establishing method of the hypertensive disorder complicating pregnancy mouse model comprises the following steps of: extracting a syncytiotrophoblast microvilli membrane; and inputting the syncytiotrophoblast microvilli membrane to a pregnant mouse body of the same strain by caudal vein injection to establish the hypertensive disorder complicating pregnancy mouse model. The hypertensive disorder complicating pregnancy mouse model established by the establishing method disclosed by the invention has hypertensive disorder complicating pregnancy characteristic symptoms and signs including elevation of blood pressure, eclampsia hyperspasmia, damages to heart and liver and the like, which are consistent with the symptoms and pathological process of the hypertensive disorder complicating pregnancy including eclampsia and the like at the early stage of the human eclampsia, and therefore, the hypertensive disorder complicating pregnancy mouse model can be used for researching the occurrence and development mechanism of the hypertensive disorder complicating pregnancy including eclampsia and the like at the early stage of the eclampsia, as well as the medical foundation with the purpose of developing antagonistic medicaments and the clinical research.

The invention disclosed application of FAM127A in a pregnancy disease. Specifically, the disease is pre-eclampsia. The expression of FAM127A is down-regulated in a pregnant womon with pre-eclampsia. It is found through large sample verification that the gene has higher positive detection rate, and it is proposed that the gene can be applied to clinical diagnosis of pre-eclampsia. By overexpressingthe FAM127A in trophoblast cells, it is found that the proliferation ability and invasion ability of the trophoblast cells are changed, and it is prompted that the FAM127A can serve as a potential target for the treatment of pre-eclampsia.

Provided herein are methods for determining an amount of glucose-6-phosphate dehydrogenase ("G6PDH") in a biological sample. Also provided herein are methods for detecting G6PDH deficiency, as well as diagnosing G6PDH- associated disorders, such as acute hemolytic anemia and pre-eclampsia.

The invention discloses a novel peptidome for improving pre-eclampsia placental dysfunction, and relates to the related field of medicine. The novel peptidome solves the problem that most drugs for improving the pre-eclampsia placental dysfunction in the prior art have certain toxic and side effects on a mother womb. The peptidome has a sequence of Ac-RFAACAA-COOH, the peptidome is applied to drugs or medicaments for improving the pre-eclampsia placental dysfunction, the peptidome is applied to reduction of the level of urinary proteins / creatinine in pre-eclampsia pregnant rats, the peptidomeis applied to increase of the placental utilization rate of the pre-eclampsia pregnant rats, and the peptidome is applied to inversion of TNF alpha inhibition to migration and invasion of trophoblast.

The invention discloses a placenta-derived endogenous polypeptide and application thereof. The invention relates to a placenta tissue endogenous polypeptide APEP1 (Anti-Pre-eclampsia peptide 1). The amino acid sequence of the placenta tissue endogenous polypeptide APEP1 (Anti-Pre-eclampsia peptide 1) is as shown in SEQ ID NO. 1. The polypeptide APEP1 can promote the proliferation capacity of placental trophoblasts. The human placenta tissue endogenous polypeptide APEP1 can be used for preparing drugs or reagents for promoting placenta trophoblast cell proliferation capacity of preeclampsia patients, and is expected to provide a novel treatment strategy for preeclampsia treatment.

The invention provides a method for diagnosing whether a subject has preeclampsia or is at the risk of preeclampsia, and further provides application of microRNA and / or a specific probe / detection primer of the microRNA in preparation of a diagnostic composition and the diagnostic composition for detecting preeclampsia. Expression of the microRNA in the plasma in a preeclampsia patient is obviously increased, and the microRNA can be used as a diagnostic index which is valuable, simple, convenient and easy to dynamically monitor preeclampsia; meanwhile, the increase of the microRNA in a placenta tissue is also a potential diagnostic index for predicting preeclampsia.

The invention discloses a method for detecting a high-density lipoprotein subcomponent in a preeclampsia judgment process, which comprises the following steps: presetting a high-density lipoprotein HDL subcomponent analysis kit, obtaining a blood sample, and detecting the to-be-detected blood sample by using the high-density lipoprotein HDL subcomponent analysis kit; carrying out standing centrifugal treatment on the blood sample, separating out plasma / serum, and adding the plasma / serum sample into a sample buffer solution containing lipophilic fluorescent dye, wherein the dye can be specifically combined with lipoprotein; injecting a gel dye into a microfluidic electrophoresis chip, adding a to-be-detected blood sample, performing detecting on a microfluidic electrophoresis chip analyzer,sending the sample into a separation channel under the action of an external electric field and electroosmotic flow, and separating HDL in the to-be-detected sample into a plurality of sub-componentsunder the action of a molecular sieve and charges. According to the structure, the judgment accuracy of preeclampsia is improved.

The invention relates to the field of molecular diagnosis and medical treatment, in particular to an application of miR-196a-5p as a placental implantable disease marker. The miR-196a-5p can be used for diagnosis of placental implantable diseases, or used for distinguishing placental implantable diseases from preplacenta and preeclampsia, and has important clinical application value.

The invention discloses the application of a novel polypeptide for improving placental dysfunction in preeclampsia, relates to the related field of medicine, and solves the problem that most drugs in the prior art for improving placental dysfunction in preeclampsia have certain toxic and side effects on the mother and fetus. The application of the polypeptide is in the preparation of a medicine or a medicament for improving placental dysfunction in preeclampsia; the polypeptide sequence is Ac-RFAACAA-COOH.

The invention discloses test paper for quickly screening late onset severepre-eclampsia. The test paper for quickly screening late onset severepre-eclampsia comprises optional test paper for detectingthe APELA concentration in blood or urine. The invention also discloses a kit for screening late onset severepre-eclampsia. The kit comprises an optional reagent for detecting the APELA concentrationin blood or urine. The invention also discloses application of the test paper for detecting the APELA concentration in blood or urine in preparing the test paper for screening late onset severepre-eclampsia. The invention also discloses application of the reagent for detecting the APELA concentration in blood or urine in preparing a reagent for screening late onset severepre-eclampsia. Accordingto the test paper and the kit for quickly screening late onset severepre-eclampsia disclosed by the invention, only blood and urine of a patient need to be acquired, and whether the patient is suffered from late onset severepre-eclampsia or not can be screened, so that the test paper and the kit can be used for noninvasively, effectively and quickly examining and screening late onset severepre-eclampsia, and are convenient to use and favorable in clinic application prospect.

The invention belongs to the fields of genetic engineering and clinical medicine, and discloses a related serum microribonucleic acid marker for human severe preeclampsia and application of the marker. The marker is selected from more of hsa-miR-193a-5p, hsa-miR-424 and hsa-miR-10a. The marker has the specificity and sensitivity on a sufferer with severe preeclampsia, and can be used for preparing a diagnosis or monitoring kit for severe preeclampsia.

The invention discloses that a VWCE gene can be used as a molecular marker for preeclampsia diagnosis. The experiment of the invention proves that the expression of the VWCE gene is high in placenta tissues of a preeclampsia patient in comparison with that in normal placenta tissues. The invention also discloses that the VWCE gene can be used for preparation of a drug for treating preeclampsia. The research results provided by the invention provide a new preeclampsia clinical diagnosis method, and also provide a new drug target for treating preeclampsia.

The invention belongs to the field of biomedicine and discloses application of HCST (hematopoietic cell signal transducer) gene as a target to diagnose and treat preeclampsia. It is proved by the experiment that HCST gene has significant differences of expression in normal placenta tissue and preeclampsia placenta tissue. According to relevancy of HCST gene to preeclampsia, HCST gene may be used as a novel molecular marker to clinically diagnose preeclampsia and may also be used as a novel target to preeclampsia drugs.

The invention belongs to the technical field of computer-aided diagnosis, and relates to a preeclampsia risk prediction method based on MLP multi-platform calibration. The method comprises the following steps: collecting sample data to obtain sample features; carrying out conversion and blank filling on the basic features of the sample; carrying out normalization processing on placenta growth factors in the disease sample data and the disease-free sample data and the processed basic features; constructing an MLP model for multi-platform calibration by using an MLP, and PlGF values of different measurement platforms after normalization are calibrated to the same platform; constructing a preeclampsia risk prediction model based on a random forest by using basic features in the processed disease sample data and disease-free sample data and placenta growth factors; and performing preeclampsia risk prediction on a test sample by using the constructed prediction model. The problem that the existing preeclampsia prediction means cannot meet the requirement for early screening is solved, and a reliable auxiliary tool is provided for doctors to clinically diagnose preeclampsia cases.

The invention provides a gene related to preeclampsia and application thereof, and belongs to the technical field of biological medicine. The gene is AC011753.5, and the AC011753.5 is highly expressed in a placenta of a patient with preeclampsia. By inhibiting the expression of AC011753.5 in human trophoblasts, the proliferation and invasion ability of the trophoblasts can be obviously promoted. Therefore, the compound can be used for preparing the medicine for treating preeclampsia.

The invention relates to the technical field of biological medicine, in particular to application of bone morphogenetic protein 6 in early diagnosis and treatment of preeclampsia. The invention provides application of BMP6 as a marker for early diagnosis / treatment of preeclampsia, application of BMP6 combined with PlGF and activin A in early diagnosis of preeclampsia, and application of BMP6 in preparation of drugs for prevention and treatment of preeclampsia. The invention finds that the BMP6, PlGF and activin A can improve the diagnosis effect of the existing diagnostic marker on preeclampsia in the preeclampsia early diagnosis; in addition, it is found that BMP6 can increase invasiveness and endothelial characteristic acquisition of human trophoblast cells, improve insufficient placental trophoblast invasion and poor vascular remodeling in the early stage of preeclampsia and then improve development of preeclampsia, and the BMP6 has the potential of preparing drugs for preventing and treating preeclampsia.

The invention disclosed application of FAM127A in a pregnancy disease. Specifically, the disease is pre-eclampsia. The expression of FAM127A is down-regulated in a pregnant womon with pre-eclampsia. It is found through large sample verification that the gene has higher positive detection rate, and it is proposed that the gene can be applied to clinical diagnosis of pre-eclampsia. By overexpressingthe FAM127A in trophoblast cells, it is found that the proliferation ability and invasion ability of the trophoblast cells are changed, and it is prompted that the FAM127A can serve as a potential target for the treatment of pre-eclampsia.

The present invention provides an application of a kidney-nourishing and fetus-cultivating pill in preparing a medicine for preventing preeclampsia. The kidney-nourishing and fetus-cultivating pill has a relatively good effect on preventing the preeclampsia, can obviously reduce preeclampsia morbidity of high-risk pregnant women in the preeclampsia, can inhibit progress of the disease into early-onset type preeclampsia, severe preeclampsia and gestational hypertension, improves maternal and infant outcome, reduces postpartum hemorrhage incidence, premature birth rate and neonatal NICU survivalrate, and increases neonatal body weight normality rate. The result shows that the kidney-nourishing and fetus-cultivating pill can improve pregnancy outcome of the pregnant women with high risk of the preeclampsia by preventing occurrence of the preeclampsia.

The invention discloses a preeclampsia diagnostic kit and application of nile blue. The preeclampsia diagnostic kit comprises a fluorescent dye for dyeing a blood sample of a pregnant woman. According to the preeclampsia diagnostic kit, a pregnant woman blood sample is dyed through a fluorescent dye, a normal pregnant woman blood sample and a preeclampsia pregnant woman patient blood sample are treated through the fluorescent dye in combination with the test of the embodiment part, by combining the FLIM technology, a blood sample of a normal pregnant woman and a blood sample of a preeclampsia pregnant woman patient can be obviously distinguished so that the preeclampsia can be diagnosed.

The invention discloses a biomarker for diagnosis of preeclampsia of pregnancy, application and a kit, and relates to the field of biological medicines. According to the application, the relevance between the alpha PS IgG antibody level and the preeclampsia blood coagulation function is found, and compared with a healthy control, the plasma alpha PS IgG antibody of a preeclampsia patient is increased by 0.47 times, so that the difference is obvious. The alpha PS IgG antibody can be used as a biomarker for diagnosis of preeclampsia in pregnancy, detection of the alpha PS IgG antibody can be possibly applied to clinical diagnosis of preeclampsia in the future, and the alpha PS IgG antibody can also be used as an effective supplementary means for screening and diagnosis of preeclampsia at present. And compared with the existing total IgG detection, the alphaPS antibody has higher specificity and higher detection sensitivity.

The invention provides specific miRNAs in peripheral plasma for pre-eclampsia and application thereof. The nucleotide sequence of the miRNAs is shown as SEQ ID NO. 1. According to the invention, the specific miRNAs in the peripheral plasma for pre-eclampsia can be stably expressed in the peripheral plasma of pre-eclampsia patients and the peripheral plasma of pregnant women with the same gestational weeks but without pre-eclampsia, and there is an obvious difference in the expression of the specific miRNAs between the pre-eclampsia patients and the pregnant women with the same gestational weeks but without pre-eclampsia. The specific miRNAs can be applied to early identification of the pre-eclampsia, and can be served as quantitative indexes for timely termination of pregnancy of the pre-eclampsia patients.

The invention discloses application of ZNF770 gene as a diagnostic treatment target for preeclampsia. Accordingly, ZNF770 can be used to develop products to diagnose preeclampsia and drugs to treat preeclampsia. Study results of herein provide theoretical basis for clinicians to formulate personalized treatment plans and provide novel pharmaceutical targets to develop preeclampsia drugs.

The invention, which belongs to the biomedicine field, discloses application of a labeling reagent of long-chain fatty acid coenzyme A ligase 1 in preparation of a kit for diagnosing whether a pregnant woman suffers from preeclampsia or predicting whether a pregnant woman has the risk of suffering from preeclampsia. The invention further discloses a kit for diagnosing whether a pregnant woman suffers from preeclampsia or predicting whether the pregnant woman has the risk of suffering from preeclampsia or not. The kit comprises a labeling reagent of the long-chain fatty acid coenzyme A ligase 1. Therefore, a novel biomarker for diagnosis and early warning of the preeclampsia of hypertensive disorder complicating pregnancy and has the important clinical value.